基因修饰胎肝干细胞治疗肝纤维化  

Therapeutic effect of gene modified fetal liver stem cells on hepatic fibrosis

作　　者：唐彤宇[1] 高沿航[1] 荆雪[1] 祝尔建[1] 朴云峰[1] 

机构地区：[1]吉林大学第一医院肝胆胰内科,长春130021

出　　处：《临床肝胆病杂志》2010年第4期400-402,共3页Journal of Clinical Hepatology

基　　金：吉林省科技厅(200505219)

摘　　要：目的探讨肝细胞生长因子(HGF)基因修饰的胎肝干细胞治疗肝纤维化大鼠的效果。方法构建大鼠HGF基因和绿色荧光蛋白基因共同表达的融合载体,转染到胎肝母细胞中。将能够表达HGF的细胞移植到CCl4肝纤维化大鼠体内,将增强型绿色荧光蛋白(EGFP)修饰的胎肝干细胞作为对照组,检测大鼠肝功能和血清HGF及TGFβ1的浓度,肝组织中荧光蛋白数量和分布,肝组织内Ⅰ、Ⅲ型胶原蛋白的沉积情况。结果组织学及血清学检测显示,与对照组相比,经HGF基因修饰的胎肝干细胞能够显著改善肝纤维化指标和大鼠肝功能(P<0.05)。结论 HGF修饰的胎肝干细胞治疗可能成为肝纤维化潜在的治疗手段。Objective To explore the efficacy of gene-modified hepatocyte growth factor（HGF） cell therapy on rat liver fibrosis model induced by CCl4.Methods EGFP-tagged HGF fusion gene was constructed and transfected into the fetal liver progenitor cells using lipofactamine.EGFP-tagged HGF fusion gene-modified fetal liver progenitor cells and EGFP gene-modified fetal liver progenitor cells（as control） were transfused intravenously in to rat liver fibrosis model.Results Histological or serological assays revealed that both treatments could significantly ameliorate the pathogenesis of liver fibrosis and improve the surrogate markers of liver function（ALT,AST） and liver fibrosis（TGF β and collagen type I and III）.EGFP-tagged HGF fusion gene-modified fetal liver progenitor cell therapy had a more favorable impact on liver fibrosis than EGFP gene-modified fetal liver progenitor cells.Conclusion HGF gene-modified fetal liver progenitor cell therapy could be a potential therapeutic approach in treatment of liver fibrosis.

关 键 词：肝硬化 肝细胞生长因子 干细胞 

分 类 号：R575.2[医药卫生—消化系统]